Johnson & Johnson
JNJ
announced that the FDA has granted approval to its TNF inhibitor, Simponi Aria for the treatment of children 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). The FDA also expanded Simponi Aria’s active psoriatic arthritis (PsA) indication use for pediatric patients 2 years and older. Simponi Aria is presently approved as a 30-minute intravenous infusion for moderately-to-severely active rheumatoid arthritis, active PsA and ankylosing spondylitis in adults.
The approval of Simponi Aria for pediatric use in active pJIA and active PsA was based on data from the GO-VIVA phase III study. The polyarticular form of JIA is most common, which causes inflammation in more than four joints. PsA in pediatric patients is a sub-type of JIA characterized by both joint inflammation and skin lesions associated with psoriasis.
So far this year, J&J’sshares have risen 2.1% against the
industry
’s 1% decrease.
Simponi Aria, a key drug in J&J’s immunology franchise, recorded sales of $1.08 billion in the first half of 2020. Other important drugs in this franchise are Stelara and Remicade while a key new drug is Tremfya. J&J markets Remicade in partnership with Merck
MRK
.
Some successful TNF inhibitor drugs currently marketed are AbbVie’s
ABBV
Humira and Amgen
AMGN
/Pfizer’s Enbrel.
J&J also filed a new drug application seeking approval of its pulmonary arterial hypertension (PAH) drug Uptravi as an injection for intravenous (IV) use in patients who are unable to take the currently marketed oral formulation of the drug. The NDA was based on data from a phase III study, which evaluated safety and tolerability of temporarily switching from oral Uptravi to Uptravi IV in patients with PAH, and then transitioning back to the initial oral dose. Uptravi was added to J&J’s product portfolio with the 2017 acquisition of Actelion.
J&J currently has a Zacks Rank #4 (Sell).
You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.
The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
